Damien McDonald is recorded as Board Member at Enovis CORP (ENOV) since January 1, 2025 and CEO at Enovis CORP (ENOV). The newest filing on record that lists Damien McDonald as CEO and Board Member at Enovis CORP (ENOV) is dated April 6, 2026. Damien McDonald was last confirmed as Board Member at AVITA Medical, Inc. (RCEL) in a filing dated September 25, 2020. Earlier roles on record: CEO and Board Member at LivaNova PLC (LIVN) until April 14, 2023. Enovis CORP reported in an 8-K filed April 2, 2025 that Damien McDonald was appointed member of the Board, effective May 21, 2025. Enovis CORP reported in an 8-K filed April 2, 2025 that Damien McDonald was appointed Chief Executive Officer, effective May 12, 2025. LivaNova PLC reported in an 8-K filed April 14, 2023 that Damien McDonald resigned as member of the Company's Board of Directors. Equibles holds 4 filed executive changes naming Damien McDonald; each is listed under recent activity with its source filing. The proxy statement of Enovis CORP reports total compensation of $9,242,161 for Damien McDonald in fiscal 2025, including a base salary of $634,615. Disclosed compensation is on record for 7 fiscal years. Damien McDonald has spoken on 17 earnings calls and 1 other investor event across 2 companies, most recently for Enovis CORP on September 8, 2026. Those appearances were for LivaNova PLC (LIVN) and Enovis CORP (ENOV). Enovis CORP is classified in the Medical Devices industry within the Healthcare sector. Other companies whose calls Damien McDonald spoke on are classified in the Healthcare sector. Other leadership on record at Enovis CORP includes Matthew L. Trerotola (CEO, Chairman and Board Member), Sharon Wienbar (Chairman and Board Member), Christopher Hix (CFO) and 7 others.
“appointed Mr. McDonald as a member of the Board to fill the vacancy resulting from Mr. Trerotola's retirement from the Board.”
“the Board of Directors of the Company (the "Board") has appointed Damien McDonald as Chief Executive Officer ("CEO") of the Company, effective as of May 12, 2025 (the "Appointment Date").”
“I mean, again, we recently reported six weeks ago. So the way we're seeing the U.S. normal seasonality, it's sort of back to a pre-COVID normal. And we always see a bit of slowdown in the summer, which we've seen.”
“And good morning, everyone, and thank you for joining us today. On today's call, I'll start with an overview of our second quarter results, discuss performance across our two operating segments, Recon and PNR.”
“We're encouraged by our start to 2026, with the first quarter results reflecting solid execution and continued progress advancing our innovation-led strategy. Our priorities, commercial execution and innovation, operational excellence, and financial discipline continue to guide our actions.”
“Good morning, everyone, and thank you for joining us today for our fourth quarter and full year 2025 earnings call. Our results reflect strong performance across our global organization.”
